Healthcare

Imugene Limited (ASX:IMU)

Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Biotechnology

Market Price : AUD 0.445-0.01 (2.198%)

(as on 2021-10-23 03:55:41)

Market Cap : AUD 2.445 B

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
0.455 0.46 0.445 0.445L 0.465 H 0.054L 0.515 H
Last Trade 0.445
Change% -2.1978
52 W H/L 0.515/0.054
EBITDA -18.24 M
NPAT After Abnormal Items -18.455 M
Equity 65.018 M
ROE% -28.39%
Total Liabilities 6.791 M
Total Revenue 7.282 M
Cash and Cash Equivalents 29.487 M

Stock Information

Share price 0.445
Market Cap 2.445 B
Price/Gross Cash Flow -137.41
Dividend Yield Excluding Special 0.00%
Ending Shares 4.963 B
52-Week Range 0.054-0.515
P/E ratio 0.000
Sector P/E --
EPS -0.40
EV/EBITDA --
Net Profit Margin (%) --
Gross Cash Flows Per Share -0.00
Net Gearing -44.94%
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.01
Sales Per Share 0.00
Book Value Per Share 0.01

Announcements

Heading Date/Time
Change in substantial holding - PH  22/10/2021 5:43PM
Change of Director's Interest Notice - PH  22/10/2021 5:40PM
Notice Under Section 708A  22/10/2021 5:36PM
Application for quotation of securities - IMU  22/10/2021 5:31PM
Quarterly Activities/Appendix 4C Cash Flow Report  22/10/2021 4:56PM
Proposed issue of securities - IMU  20/10/2021 6:09PM
FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF CHECKVACC  20/10/2021 12:42PM
Application for quotation of securities - IMU  15/10/2021 4:10PM
Notice of Annual General Meeting/Proxy Form  14/10/2021 7:34PM
Change of Director's Interest Notice - LR  11/10/2021 4:41PM
Application for quotation of securities - IMU  08/10/2021 12:15PM
Investor Presentation  05/10/2021 5:07PM
Corporate Governance Statement  04/10/2021 1:32PM
Appendix 4G  04/10/2021 1:31PM
Annual Report to shareholders  04/10/2021 1:30PM
Application for quotation of securities - IMU  01/10/2021 1:07PM
Imugene HER-Vaxx Immunotherapy Patent Granted in Japan  22/09/2021 9:26AM
Application for quotation of securities - IMU  17/09/2021 3:01PM
PD1-Vaxx Presentation at ESMO Congress 2021 Annual Meeting  17/09/2021 9:20AM
Application for quotation of securities - IMU  13/09/2021 12:04PM
Becoming a substantial holder - PH  13/09/2021 10:03AM
Change of Director's Interest Notice - PH  13/09/2021 9:56AM
Application for quotation of securities - IMU  09/09/2021 12:09PM
Proposed issue of securities - IMU  07/09/2021 5:53PM
Results of Meeting  07/09/2021 10:04AM
Application for quotation of securities - IMU  03/09/2021 3:01PM
Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials  01/09/2021 9:07AM
Appendix 4E and Full Year Statutory Accounts  30/08/2021 12:16PM
Application for quotation of securities - IMU  27/08/2021 11:07AM

Similar Companies

Related Articles

About Company

Imugene Limited (ASX:IMU) is an Australia-headquartered clinical stage immuno-oncology firm which is in the process of developing a wide array of new treatments that attempt to activate the cancer patients’ immune system to detect and remove tumours. The Company intends to improve and transform the lives of cancer-bearing patients who need effective treatments.

Imugene is backed by a leading team of international cancer experts who hold extensive experience in advancing new cancer therapies. The Company’s efficient and strong management team provides confidence in its ability to discover and manage the development and sales process for its  products.

The Company’s clinical pipeline comprises multiple immunotherapy B-Cell vaccine candidates and an Oncolytic Virotherapy CF33, which intend to treat a range of cancers along with the standard of care drugs as well as emerging immunotherapies. The B-cell immunotherapies comprise PD1-Vaxx and two HER2 B-cell immunotherapies - HER-Vaxx and B-Vaxx.

PD-1 Vaxx, or the PD-1 B-cell immunotherapy, aims to induce the patient’s body to generate polyclonal antibodies which block PD-1 signalling, and therefore, create an anticancer effect akin to Opdivo, Keytruda and the other immune checkpoint inhibitors, which have transitioned the treatment for a range of cancers. Besides, HER-Vaxx has been designed for treating tumours which over-express the HER-2 protein, like gastric, lung, pancreatic, breast, and ovarian cancers. Akin to HER-Vaxx, B-Vaxx has also been designed for treating tumours which over-express the HER-2 protein.

Acquired by the Company in November 2019, CF33 was developed by renowned Professor Yuman Fong at City of Hope (COH) Cancer Centre based in Los Angeles, California. CF33 is identified as a chimeric vaccinia poxvirus in the area of oncolytic virotherapy that comes in two different forms: CHECKVacc and Vaxinia. Through the use of CF33, Imugene hopes to bolster the clinical benefits and quality of living for patients suffering from cancers that are difficult to treat through current therapeutic approaches.

 

 

Corporate Information

company address Level 3, 62 Lygon Street, CARLTON, VIC, AUSTRALIA, 3053

company phone03 9824 5254

company websitehttp://www.imugene.com

Dividends

Ex-Dividend Date Franking DPS (AUD) Dividend Yield
30/06/2021 -- 0.000 0.00%
30/06/2020 -- 0.000 0.00%
30/06/2019 -- 0.000 0.00%
30/06/2018 -- 0.000 0.00%
30/06/2017 -- 0.000 0.00%
30/06/2016 -- 0.000 0.00%
30/06/2015 -- 0.000 0.00%
30/06/2014 -- 0.000 0.00%
30/06/2013 -- 0.000 0.00%
30/06/2012 -- 0.000 0.00%

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2022-10-03 2022
Report (Prelim) 2022-08-29 2022
Report (Interim) 2022-02-25 2022

Financials

Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Trading Revenue -- -- -- -- --
Other Revenue 7.282 M 4.074 M 4.205 M 1.841 M 1.164 M
Total Revenue 7.282 M 4.074 M 4.205 M 1.841 M 1.164 M
Interest Income 126,565 302,186 414,893 94,327 35,429
Interest Expenses -116,056 -5,029 -6,108 0 0
Expenses -25.643 M -13.308 M -12.328 M -5.866 M -3.704 M
EBITDA -18.362 M -9.234 M -8.123 M -4.025 M -2.54 M
Depreciation and Amortization -104,203 -82,495 -63,259 -2,680 -1,743
Depreciation -104,203 -82,495 -63,259 -2,680 -1,743
Amortisation 0 0 0 0 0
EBIT -18.466 M -9.316 M -8.186 M -4.028 M -2.542 M
Pre Tax Profit -18.455 M -9.019 M -7.777 M -3.934 M -2.507 M
Tax Expense 0 0 0 0 0
Net Profit After Tax -18.455 M -9.019 M -7.777 M -3.934 M -2.507 M
Minority Interest 0 0 0 0 0
Preference Dividend 0 0 0 0 0
Net Abnormal Items 0 -1.489 M 1,726 0 0
Reported Net Profit After Abnormal Items -18.455 M -10.508 M -7.775 M -3.934 M -2.507 M
Ending Shares 4.963 B 4.426 B 3.61 B 2.855 B 2.387 B
Weighted Average Shares 4.664 B 4.075 B 3.582 B 2.638 B 2.088 B
EPS After Abnormal Items (cents) -0.4 -0.26 -0.22 -0.15 -0.12
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Total Current Assets 36.319 M 34.495 M 23.424 M 9.833 M 6.054 M
Total Non Current Assets 35.49 M 30.71 M 7.356 M 7.081 M 6.623 M
Total Assets 71.809 M 65.205 M 30.779 M 16.914 M 12.678 M
Total Current Liabilities 4.457 M 2.899 M 2.424 M 438,240 297,493
Total Non Current Liabilities 2.334 M 2.499 M 1.061 M 1.001 M 985,450
Total Liabilities 6.791 M 5.399 M 3.485 M 1.439 M 1.283 M
Net Assets 65.018 M 59.806 M 27.295 M 15.475 M 11.395 M
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Net Operating Cash -13.28 M -10.438 M -7.909 M -4.462 M -2.673 M
Net Invested Cash -5.326 M -1.207 M 247,392 -460,676 -2,340
Net Financing Cash Flows 17.985 M 22.707 M 18.773 M 7.93 M 5.928 M
Beginning Cash 30.107 M 19.048 M 7.822 M 4.814 M 1.583 M
End Cash Position 29.487 M 30.107 M 19.048 M 7.822 M 4.814 M
Exchange Rate Adjustments 1,353 -3,898 115,072 0 -21,151
Other Cash Adjustments 0 0 0 0 0
Ending Cash 29.487 M 30.107 M 19.048 M 7.822 M 4.814 M

© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK